Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Enhanced Risk of Cytokine Release Syndrome in Obese and Related Comorbidities Undergoing CAR-T Therapy for B-Cell Malignancies

Rosanna Tryphene Massounga Mayombo, Mengyi Du, Jiachen Liu, Yinqiang Zhang, Danying Liao, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7216.

https://doi.org/10.1182/blood-2024-205054

Published: 2024

Journal Articles

All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma

Yinqiang Zhang, Wu Zhuolin, Wenjing Luo, Chenggong Li, Heng Mei

Blood (2024) 144 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2024-205044

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway

Yingying Li, Lili Luo, Jianghua Wu, Zhong Wu, Huiwen Jiang, Zhaozhao Chen, Jiachen Liu, Jinhui Shu, Jingming Wang, Min Xu, Mengyi Du, Jun Deng, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2024-202845

Published: 2024

Journal Articles

mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Zhaozhao Chen, Anqi Ren, Jinhui Shu, Yingying Li, Hekuan Huang, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2024-209037

Published: 2024

Journal Articles

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Xindi Wang, Wenjing Luo, Zhaozhao Chen, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2024-205045

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma

Wenjing Luo, Jia Xu, Chenggong Li, Lu Tang, Yingying Li, Xindi Wang, Wu Zhuolin, Yinqiang Zhang, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 3420.

https://doi.org/10.1182/blood-2024-207202

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells

Zhaozhao Chen, Anqi Ren, Hekuan Huang, Yingying Li, Jinhui Shu, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2024-209178

Published: 2024

Journal Articles

Prior Antibiotic Exposure Correlates with Unfavorable Efficacy and Prognosis of B-NHL after CAR-T Cell Therapy

Jia Xu, Wenjing Luo, Chenggong Li, Yinqiang Zhang, Xindi Wang, Jiachen Liu, Wu Zhuolin, Zhongpei Huang, Yun Kang, Qiaolin Liu, Zhihan Chen, Heng Mei

Blood (2024) 144 (Supplement 1): 7158.

https://doi.org/10.1182/blood-2024-209107

Published: 2024

Journal Articles

The Impact and the Predictive Ability of Immunogenicity of Humanized Anti-CD19 CAR-T Cells for the Efficacy and Prognosis

Zhongpei Huang, Jia Xu, Chenggong Li, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7142.

https://doi.org/10.1182/blood-2024-205047

Published: 2024

Journal Articles

Natural Killer-Cell Recovery in Patients Receiving CD19 CAR T-Cell Therapy: Dynamics and Clinical Significance

Xindi Wang, Wenjing Luo, Lu Tang, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7217.

https://doi.org/10.1182/blood-2024-205259

Published: 2024

Journal Articles

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Wu Zhuolin, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 6546.

https://doi.org/10.1182/blood-2024-205304

Published: 2024

Journal Articles

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Hongyong Zhang, Zhipeng Cheng, Heng Mei, Chunyan Sun, Yingying Wu, Danying Liao, Fei Zhao, Yu Hu, Linghui Xia, Jun Fang

Blood (2024) 144 (Supplement 1): 6282.

https://doi.org/10.1182/blood-2024-198795

Published: 2024

Journal Articles

Phase I Study of Allogeneic Anti-CD19 CAR-T Therapy for Patients with CD19+ Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Guangyu Sun, Heng Mei, Yali Zhou, Tianzhong Pan, Lu Han, Jiangtao Ren, Xiaoyu Zhu

Blood (2024) 144 (Supplement 1): 7199.

https://doi.org/10.1182/blood-2024-200582

Published: 2024

Journal Articles

An Antibiotic-Based Scoring Model for Predicting Early and Late Hematologic Toxicity Following CD19 CAR-T Therapy in B-ALL Patients

Heng Mei, Jiachen Liu

Blood (2024) 144 (Supplement 1): 7227.

https://doi.org/10.1182/blood-2024-209231

Published: 2024

Journal Articles

Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis

Yingying Li, Zhong Wu, Huiwen Jiang, Zhaozhao Chen, Min Xu, Jinhui Shu, Jingming Wang, Qinying Xie, Jun Deng, Yu Hu, Lili Luo, Heng Mei

Blood (2024) 144 (Supplement 1): 3993.

https://doi.org/10.1182/blood-2024-205102

Published: 2024

Journal Articles

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 4855.

https://doi.org/10.1182/blood-2024-202870

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

NARROW

Enhanced Risk of Cytokine Release Syndrome in Obese and Related Comorbidities Undergoing CAR-T Therapy for B-Cell Malignancies

All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway

mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells

Prior Antibiotic Exposure Correlates with Unfavorable Efficacy and Prognosis of B-NHL after CAR-T Cell Therapy

The Impact and the Predictive Ability of Immunogenicity of Humanized Anti-CD19 CAR-T Cells for the Efficacy and Prognosis

Natural Killer-Cell Recovery in Patients Receiving CD19 CAR T-Cell Therapy: Dynamics and Clinical Significance

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Phase I Study of Allogeneic Anti-CD19 CAR-T Therapy for Patients with CD19+ Relapsed/Refractory Acute B-Lymphoblastic Leukemia

An Antibiotic-Based Scoring Model for Predicting Early and Late Hematologic Toxicity Following CD19 CAR-T Therapy in B-ALL Patients

Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only